Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center

被引:130
|
作者
Buckmiller, Lisa M. [1 ]
Munson, Patrick D. [1 ]
Dyamenahalli, Umesh [2 ]
Dai, Yuemeng [1 ]
Richter, Gresham T. [1 ]
机构
[1] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Otolaryngol, Div Pediat Otolaryngol, Little Rock, AR 72202 USA
[2] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA
来源
LARYNGOSCOPE | 2010年 / 120卷 / 04期
关键词
Propranolol; hemangioma; birthmark; beta-blocker; CLASSIFICATION; VINCRISTINE; CHILDREN; INFANCY;
D O I
10.1002/lary.20807
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas Systematic examination of this treatment in a tertiary care setting has not been described This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center. Study Design: Retrospective single institution review Materials and Methods: We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol. Results: Thirty-two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009 Twenty-seven patients began therapy during the proliferative phase of their lesions (mean age, 4 9 months), whereas five patients began during the involutional phase (mean age, 19.4 months) Ninety-seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%) Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%). Conclusions: Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required Minor side effects, expected from beta-blocker therapy, are common but easily managed.
引用
下载
收藏
页码:676 / 681
页数:6
相关论文
共 50 条
  • [1] Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience
    Park, Young Woon
    Yeom, Kkot Bora
    Choi, Jae Woo
    Kim, Dong Young
    Shin, Hyoseung
    Kim, Kyu Han
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (05) : 391 - 395
  • [2] Treatment with propranolol for infantile hemangiomas: single-center experience
    Turhan, Ayse Bozkurt
    Bor, Ozcan
    Ozdemir, Zeynep Canan
    JOURNAL OF COSMETIC DERMATOLOGY, 2016, 15 (03) : 296 - 302
  • [3] Infantile Hemangiomas and Vascular Anomalies
    Paradiso, Michela M.
    Shah, Sonal D.
    Faith, Esteban Fernandez
    PEDIATRIC ANNALS, 2024, 53 (04): : e129 - e137
  • [4] Propranolol in infantile hemangiomas
    Leaute-Labreze, C.
    ARCHIVES DE PEDIATRIE, 2015, 22 (04): : 452 - 455
  • [5] Propranolol for Infantile Hemangiomas
    Bagazgoitia, Lorea
    Torrelo, Antonio
    Lopez Gutierrez, Juan Carlos
    Hernandez-Martin, Angela
    Luna, Paula
    Gutierrez, Marta
    Bano, Antonio
    Tamariz, Amalia
    Larralde, Margarita
    Alvarez, Roser
    Pardo, Nuria
    Baselga, Eulalia
    PEDIATRIC DERMATOLOGY, 2011, 28 (02) : 108 - 114
  • [6] Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital
    Martina Volonté
    Alessia Claudia Codazzi
    Shay Davidovich
    Antonia Apicella
    Eugenio Isoletta
    Stefania Barruscotti
    Margherita Massa
    Annalisa De Silvestri
    Gian Luigi Marseglia
    Valeria Brazzelli
    European Journal of Dermatology, 2023, 33 : 265 - 269
  • [7] Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital
    Volonte, Martina
    Codazzi, Alessia Claudia
    Davidovich, Shay
    Apicella, Antonia
    Isoletta, Eugenio
    Barruscotti, Stefania
    Massa, Margherita
    De Silvestri, Annalisa
    Marseglia, Gian Luigi
    Brazzelli, Valeria
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (03) : 265 - 269
  • [8] Management of infantile hemangiomas—experience of a tertiary hospital
    Rita Gomes
    Luís Salazar
    Carolina Fraga
    Mário Rui Correia
    Joana Barbosa-Sequeira
    Alexandre Fernandes
    Sílvia Álvares
    José Banquart Leitão
    Margarida Paiva Coelho
    European Journal of Pediatrics, 2023, 182 : 1611 - 1618
  • [9] Early propranolol treatment of infantile hemangiomas improves outcome
    Giachetti, Ana
    Diaz, Maria Sol
    Boggio, Paula
    Martinez, Maria Lourdes Posadas
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2023, 98 (03) : 310 - 315
  • [10] Experience with Holter monitoring during propranolol therapy for infantile hemangiomas
    Jacks, Stephanie K.
    Kertesz, Naomi J.
    Witman, Patricia M.
    Faith, Esteban Fernandez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 255 - 257